05:07 AM EDT, 05/28/2024 (MT Newswires) -- AstraZeneca ( AZN ) said Monday its datopotamab deruxtecan therapy showed "clinically meaningful" improvement in overall survival rates over chemotherapy in nonsquamous non-small cell lung cancer patients during a phase 3 trial.

The 600-patient trial of the therapy previously met the primary endpoint of improvement in progression-free survival compared with docetaxel chemotherapy, although "survival results did not reach statistical significance in the overall trial population," the company said.

Datopotamab deruxtecan is being jointly developed by AstraZeneca ( AZN ) and Daiichi Sankyo.

The latest results "support applications" under review by regulators including in the US and European Union, AstraZeneca ( AZN ) said.

Price: 78.25, Change: -0.29, Percent Change: -0.38